W Reinisch

Summary

Affiliation: Medical University of Vienna
Country: Austria

Publications

  1. pmc A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease
    W Reinisch
    Universitaetsklinik Innere Medizin IV, Abteilung Gastroenterologie and Hepatologie, Vienna, Austria
    Gut 55:1138-44. 2006
  2. ncbi request reprint Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
    Walter Reinisch
    Univ Klinik Innere Medizin IV, AKH Wien, Vienna, Austria, and Division of Gastroenterology, Hospital Leuven, Belgium
    Inflamm Bowel Dis 13:1135-40. 2007
  3. ncbi request reprint A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis
    Alexander Teml
    Universitatsklinik fur Innere Medizin IV, Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Vienna, Austria
    Scand J Gastroenterol 40:1205-13. 2005
  4. doi request reprint [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]
    W Reinisch
    AKH Wien, Univ Klinik für Innere Medizin III, Klin Abteilung f Gastroenterologie und Hepatologie, Wien, Osterreich
    Z Gastroenterol 49:534-42. 2011
  5. doi request reprint Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus
    Walter Reinisch
    University Klinik Innere Medizin III, Abt Gastroenterologie, Vienna, Austria
    J Crohns Colitis 6:248-58. 2012
  6. pmc The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method
    W Reinisch
    Department Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Aliment Pharmacol Ther 38:1109-18. 2013
  7. pmc A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)
    Walter Reinisch
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Hospital, Vienna, Austria
    Am J Gastroenterol 108:1877-88. 2013
  8. doi request reprint 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants
    Walter Reinisch
    Department of Internal Medicine III, Medical University Vienna, Vienna, Austria
    Inflamm Bowel Dis 19:1700-9. 2013
  9. doi request reprint State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease
    Walter Reinisch
    Medical University of Vienna, Austria
    J Crohns Colitis 7:429-40. 2013
  10. pmc Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial
    Walter Reinisch
    Medical University of Vienna, Vienna, Austria
    Inflamm Bowel Dis 19:293-300. 2013

Collaborators

Detail Information

Publications71

  1. pmc A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease
    W Reinisch
    Universitaetsklinik Innere Medizin IV, Abteilung Gastroenterologie and Hepatologie, Vienna, Austria
    Gut 55:1138-44. 2006
    ..This study was designed to evaluate the safety of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease (CD)...
  2. ncbi request reprint Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis
    Walter Reinisch
    Univ Klinik Innere Medizin IV, AKH Wien, Vienna, Austria, and Division of Gastroenterology, Hospital Leuven, Belgium
    Inflamm Bowel Dis 13:1135-40. 2007
    ..Impairment of health-related quality of life, employment, and productivity has been documented in patients with moderate to severe ulcerative colitis...
  3. ncbi request reprint A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis
    Alexander Teml
    Universitatsklinik fur Innere Medizin IV, Abteilung für Gastroenterologie und Hepatologie, Medizinische Universität Wien, Vienna, Austria
    Scand J Gastroenterol 40:1205-13. 2005
    ..The aim of the present study was to evaluate the safety and efficacy of 6-TG in patients with ulcerative colitis (UC) or indeterminate colitis (IC) intolerant or resistant to AZA/6-MP...
  4. doi request reprint [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology]
    W Reinisch
    AKH Wien, Univ Klinik für Innere Medizin III, Klin Abteilung f Gastroenterologie und Hepatologie, Wien, Osterreich
    Z Gastroenterol 49:534-42. 2011
    ..Infliximab is an effective treatment option for the above-mentioned indications; however, use of this agent requires special knowledge to assess the benefit-risk profile for each patient individually...
  5. doi request reprint Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus
    Walter Reinisch
    University Klinik Innere Medizin III, Abt Gastroenterologie, Vienna, Austria
    J Crohns Colitis 6:248-58. 2012
    ..Therefore, it is important to identify which patients are candidates for infliximab therapy...
  6. pmc The management of iron deficiency in inflammatory bowel disease--an online tool developed by the RAND/UCLA appropriateness method
    W Reinisch
    Department Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Aliment Pharmacol Ther 38:1109-18. 2013
    ..Iron deficiency is a common and undertreated problem in inflammatory bowel disease (IBD)...
  7. pmc A randomized, open-label, non-inferiority study of intravenous iron isomaltoside 1,000 (Monofer) compared with oral iron for treatment of anemia in IBD (PROCEED)
    Walter Reinisch
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University Hospital, Vienna, Austria
    Am J Gastroenterol 108:1877-88. 2013
    ....
  8. doi request reprint 52-week efficacy of adalimumab in patients with moderately to severely active ulcerative colitis who failed corticosteroids and/or immunosuppressants
    Walter Reinisch
    Department of Internal Medicine III, Medical University Vienna, Vienna, Austria
    Inflamm Bowel Dis 19:1700-9. 2013
    ..The results of an open-label follow-up until week 52 of patients with moderately to severely active ulcerative colitis who participated in a double-blind placebo-controlled adalimumab induction trial (ULTRA 1, NCT00385736) are reported...
  9. doi request reprint State of the iron: how to diagnose and efficiently treat iron deficiency anemia in inflammatory bowel disease
    Walter Reinisch
    Medical University of Vienna, Austria
    J Crohns Colitis 7:429-40. 2013
    ..The following article aims to review the magnitude of the problem of IDA in IBD, suggest screening standards and highlight existing and future therapies...
  10. pmc Extracorporeal photopheresis (ECP) in patients with steroid-dependent Crohn's disease: an open-label, multicenter, prospective trial
    Walter Reinisch
    Medical University of Vienna, Vienna, Austria
    Inflamm Bowel Dis 19:293-300. 2013
    ..A previous trial demonstrated that ECP permits corticosteroid withdrawal in steroid-dependent Crohn's disease (CD) patients who were in clinical remission. We studied the effect of ECP on steroid withdrawal in steroid-dependent CD...
  11. doi request reprint C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I
    W Reinisch
    Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Aliment Pharmacol Ther 35:568-76. 2012
    ..Secondary loss of response to anti-TNF-α therapy is observed in Crohn's disease patients...
  12. doi request reprint [Adalimumab for the treatment of Crohn's disease - consensus paper of the Working Group "chronic inflammatory bowel diseases" of the Austrian Society for Gastroenterology and Hepatology]
    W Reinisch
    Medizinische Universität Wien, Univ Klinik Innere Medizin III, Waehringer Guertel 18 20, 1090 Wien, Osterreich
    Z Gastroenterol 47:372-80. 2009
    ..The presented therapy guidelines based on existing evidence are aimed to assist in the efficient and safe use of adalimumab in the treatment of Crohn's disease...
  13. ncbi request reprint "How to manage loss of response to anti-TNF in Crohn's disease? "
    Walter Reinisch
    Universitätsklinik Innere Medizin III, Abteilung Gastroenterologie und Hepatologie, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Curr Drug Targets 11:152-5. 2010
    ..The molecular mechanisms of loss of response are not fully understood, but clinician face this clinical problem. The aim of this paper is to review the clinical strategies to face anti-TNF alpha antibodies in Crohn' disease...
  14. ncbi request reprint Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial
    Walter Reinisch
    Abteilung Gastroenterologie and Hepatologie, Universitätsklinik für Innere Medizin III, Abteilung Gastroenterologie and Hepatologie, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Gut 59:752-9. 2010
    ..The aim of the study was to compare azathioprine versus mesalazine tablets for the prevention of clinical recurrence in patients with postoperative Crohn's disease (CD) with moderate or severe endoscopic recurrence...
  15. doi request reprint Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies
    Walter Reinisch
    Department of Gastroenterology and Hepatology, Univ Klinik Innere Medizin III, AKH Wien, Vienna, Austria
    Inflamm Bowel Dis 18:201-11. 2012
    ..The aim was to evaluate long-term efficacy, quality of life, and safety in ulcerative colitis patients who received infliximab during the ACT-1 and -2 extension studies...
  16. doi request reprint Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study
    Walter Reinisch
    Clinic of Internal Medicine III, Department of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Inflamm Bowel Dis 16:233-42. 2010
    ..Elevated gut mucosal levels of interferon gamma, a key cytokine involved in the inflammatory process of CD, are associated with disease symptoms...
  17. doi request reprint Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
    Walter Reinisch
    Medical University Vienna, Vienna, Austria
    Gut 60:780-7. 2011
    ....
  18. ncbi request reprint [Immunosuppressive therapy for inflammatory bowel disease: consensus by the Austrian working group on IBD]
    W Reinisch
    Univ Klinik f Innere Medizin IV, Abteilung Gastroenterologie und Hepatologie, AKH Wien, Austria
    Z Gastroenterol 42:1033-45; discussion 1046-7. 2004
    ..The risk of malignancy using immunosuppressive drugs such as AZA is low and furthermore, especially AZA and 6-MP can be used rather safely during pregnancy...
  19. ncbi request reprint In vivo effects of recombinant human interleukin-10 on lymphocyte phenotypes and leukocyte activation markers in inflammatory bowel disease
    C Dejaco
    Department of Internal Medicine IV, University of Vienna, Austria
    J Investig Med 48:449-56. 2000
    ..The present study investigates the in vivo immunomodulatory properties of rHuIL-10 in inflammatory bowel disease (IBD)...
  20. ncbi request reprint Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study
    W Reinisch
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Austria
    Aliment Pharmacol Ther 15:1313-22. 2001
    ..Extracorporeal photochemotherapy has been proven effective in selected T-cell mediated diseases...
  21. doi request reprint A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease
    W Miehsler
    Department of Internal Medicine 3, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    J Crohns Colitis 4:221-56. 2010
    ..Both parts are further divided into obligatory and facultative items...
  22. ncbi request reprint Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease
    C Dejaco
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Institute of Tumour Biology, University Hospital, Vienna, Austria
    Aliment Pharmacol Ther 18:1113-20. 2003
    ..Antibiotics and thiopurines have been employed in the management of fistulizing Crohn's disease, although evidence of their efficacy is rare...
  23. ncbi request reprint Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?
    W Miehsler
    Department of Internal Medicine IV, University of Vienna, Austria
    Am J Gastroenterol 96:782-7. 2001
    ..The aim of the present study was to investigate the effect of MMF, especially in AZA-intolerant patients with chronic active CD, in comparison to a matched control group treated with AZA...
  24. ncbi request reprint [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology]
    G Novacek
    Klinische Abteilung für Gastroenterologie und Hepatologie, Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Osterreich
    Z Gastroenterol 51:1101-9. 2013
    ....
  25. pmc Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?
    W Miehsler
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Gut 53:542-8. 2004
    ..However, the extent of this risk is not known. Furthermore, it is not known if this risk is specific for IBD or if it is shared by other chronic inflammatory diseases or other chronic bowel diseases...
  26. ncbi request reprint Retesting for latent tuberculosis in patients with inflammatory bowel disease treated with TNF-α inhibitors
    P Papay
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Aliment Pharmacol Ther 36:858-65. 2012
    ..Patients treated with TNF-α inhibitors (TNFi) are at high risk of reactivation of latent tuberculosis (LTB). Prospective studies on monitoring of TB reactivation and/or infection in this risk group are lacking...
  27. ncbi request reprint IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease
    C Gasche
    Department of Gastroenterology and Hepatology, University of Vienna, Austria
    J Clin Immunol 20:362-70. 2000
    ..Our data suggest that LPMC derived from inflamed colonic mucosa have a reduced ability to produce and to respond to rhIL-10. A disease-specific alteration in the IL-10 pathway, however, was not found...
  28. doi request reprint [Colorectal cancer: screening and surveillance in inflammatory bowel diseases - consensus of the working group for inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology]
    S Angelberger
    Medizinische Universität Wien, Innere Medizin III, Abt für Gastroenterologie und Hepatologie, Wien, Osterreich
    Z Gastroenterol 51:450-7. 2013
    ..This consensus is intended to increase awareness of the increased risk of CRC in IBD and to support a standardised approach in cancer prevention...
  29. doi request reprint [Diagnosis and treatment of iron deficiency and anaemia in inflammatory bowel diseases. Consensus of the Austrian IBD Working Party]
    C Gasche
    Medizinische Universität Wien, Klinik Innere Medizin 3, Abteilung Gastroenterologie und Hepatologie
    Z Gastroenterol 49:627-32. 2011
    ..The clinical importance of intravenous iron replacement therapy in IBD with regard to effectiveness and compliance was discussed...
  30. ncbi request reprint Sexual function and quality of life after surgical treatment for anal fistulas in Crohn's disease
    S Riss
    Department of General Surgery, Medical University of Vienna, Wahringer Gurtel 18 20, 1090, Vienna, Austria
    Tech Coloproctol 17:89-94. 2013
    ..The aim of this study was to assess sexual function and quality of life (QoL) in patients after surgery for perianal Crohn's disease...
  31. doi request reprint The impact of intestinal resection on serum levels of anti-Saccharomyces cerevisiae antibodies (ASCA) in patients with Crohn's disease
    A Eser
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    Aliment Pharmacol Ther 35:292-9. 2012
    ..Antibodies to Saccharomyces cerevisiae (ASCA) are highly prevalent in sera of patients with Crohn's disease and have been proposed to identify subgroups of patients with a disabling disease course...
  32. ncbi request reprint Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes
    M Willheim
    Institute of General and Experimental Pathology, Clinic of Internal Medicine IV, University of Vienna, Austria
    J Clin Endocrinol Metab 84:3739-44. 1999
    ..The influence of 1alpha,25-(OH)2D3 on cytokine production by lymphocytes is probably an important point of intersection between the endocrine and the immune system...
  33. ncbi request reprint Infliximab: lack of efficacy on perforating complications in Crohn's disease
    Wolfgang Miehsler
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Inflamm Bowel Dis 10:36-40. 2004
    ..However, little knowledge exists about its use for the treatment of internal fistulas in CD. We present our experience with infliximab in this situation...
  34. doi request reprint [Adalimumab for the treatment of ulcerative colitis--a consensus report by the working group inflammatory bowel diseases of the Austrian Society of Gastroenterology and Hepatology]
    G Novacek
    Medizinische Universität Wien, Universitätsklinik für Innere Medizin III, Klinische Abteilung für Gastroenterologie und Hepatologie, Wien, Osterreich
    Z Gastroenterol 52:204-11. 2014
    ....
  35. doi request reprint Anti-Gal titers in healthy adults and inflammatory bowel disease patients
    A Mangold
    Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria
    Transplant Proc 43:3964-8. 2011
    ..Furthermore, we hypothesized that inflammatory bowel disease (IBD) patients display increased anti-Gal titers...
  36. ncbi request reprint Azathioprine treatment and male fertility in inflammatory bowel disease
    C Dejaco
    Division of Gastroenterology and Hepatology, Department of Internal Medicine IV, Institute of Tumor Biology, Vienna, Austria
    Gastroenterology 121:1048-53. 2001
    ..During the study period, 6 patients fathered 7 healthy children. CONCLUSIONS: Our data show that AZA does not reduce semen quality and thereby male fertility in IBD...
  37. ncbi request reprint Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures
    A Ferlitsch
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Endoscopy 38:483-7. 2006
    ..Endoscopic balloon dilation is a therapeutic option in limited strictures to avoid intestinal surgery, although there have been few reports regarding the long-term outcome...
  38. doi request reprint The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery
    Pavol Papay
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Am J Gastroenterol 105:1158-64. 2010
    ..Good evidence for the latter is lacking. The objective of this study was to evaluate the impact of thiopurine treatment on surgical recurrence in patients after first intestinal resection for CD and its possible interaction with smoking...
  39. pmc Donor dependent, interferon-gamma induced HLA-DR expression on human neutrophils in vivo
    W Reinisch
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Centre of Molecular Medicine of the Austrian Academy of Sciences, University of Vienna, Vienna, Austria
    Clin Exp Immunol 133:476-84. 2003
    ..Due to their abundance in inflammatory reactions heterogeneous HLA-DR expression by neutrophils could determine the outcome of superantigen-driven diseases...
  40. doi request reprint Extracorporeal photopheresis: past, present, and future
    Robert Knobler
    Department of Dermatology, Medical University of Vienna, Vienna, Austria
    J Am Acad Dermatol 61:652-65. 2009
    ..Progress is also being made in the search for understanding of the mechanisms of action of ECP, which will ultimately facilitate improvements in the use of this therapy...
  41. doi request reprint Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism
    Gottfried Novacek
    Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Gastroenterology 139:779-87, 787.e1. 2010
    ..We performed a cohort study to determine the risk for recurrent VTE among patients with IBD compared with subjects without IBD...
  42. doi request reprint A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease
    Walter Reinisch
    Universitaetsklinik für Innere Medizin IV, Vienna, Austria
    Am J Gastroenterol 103:2284-92. 2008
    ..A prospective study was undertaken to compare the efficacy of everolimus versus azathioprine or placebo in maintaining steroid-induced remission in active Crohn's disease (CD) and assess the safety and pharmacokinetics of everolimus...
  43. doi request reprint Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy
    Johannes Sailer
    Department of Radiology, Medical University of Vienna, Vienna, Austria
    Eur Radiol 18:2512-21. 2008
    ..1% (kappa 0.84). MR enteroclysis allows assessment of Crohn's disease recurrence after ileocolic resection. The MR score is reproducible and shows high agreement with the approved endoscopic Rutgeerts score...
  44. doi request reprint Which patients with IBD need psychological interventions? A controlled study
    Wolfgang Miehsler
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, University of Vienna, Austria
    Inflamm Bowel Dis 14:1273-80. 2008
    ..Whether there is a need for psychological interventions is unknown. This study investigated the quantity and quality of the need for psychological interventions in IBD as compared to rheumatoid arthritis (RA)...
  45. ncbi request reprint Diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's disease
    Johannes Sailer
    Department of Radiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    AJR Am J Roentgenol 185:1575-81. 2005
    ..The objective of our study was to assess the diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's disease...
  46. ncbi request reprint Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease
    Gottfried Novacek
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna A 1090, Austria
    World J Gastroenterol 12:6026-31. 2006
    ..To evaluate the effect of resistance to activated protein C (aPCR), the most common known inherited thrombophilic disorder, on the risk of intestinal operation of fibrostenosis in patients with Crohn's disease (CD)...
  47. ncbi request reprint An open-label trial of the selective cyclo-oxygenase-2 inhibitor, rofecoxib, in inflammatory bowel disease-associated peripheral arthritis and arthralgia
    W Reinisch
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    Aliment Pharmacol Ther 17:1371-80. 2003
    ..Conventional non-steroidal anti-inflammatory drugs have been associated with an increased risk of exacerbation of inflammatory bowel disease...
  48. ncbi request reprint Effects of trovafloxacin on the IL-1-dependent activation of E-selectin in human endothelial cells in vitro
    S M Zakeri
    Department of Internal Medicine IV, University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    Immunopharmacology 48:27-34. 2000
    ..These data provide evidence that accumulation of high concentration of trova in vivo in inflamed tissue might alter inflammatory responses...
  49. ncbi request reprint Anti-Galectin-3 IgG autoantibodies in patients with Crohn's disease characterized by means of phage display peptide libraries
    E Jensen-Jarolim
    Department of Pathophysiology, University of Vienna, Austria
    J Clin Immunol 21:348-56. 2001
    ..Our data may suggest that galectin-3 mimotopes could be used for the induction of IgG with desired specificity to regulate immune responses in Crohn's disease patients...
  50. ncbi request reprint An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease
    Clemens Dejaco
    Division of Gastroenterology and Hepatology, Department of Internal Medicine IV, University Hospital of Vienna, Vienna, Austria
    Digestion 68:63-70. 2003
    ..We performed a prospective, open-label pilot study with rhG-CSF for the treatment of CD...
  51. ncbi request reprint Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment
    Alexander Teml
    Universitatsklinik fur Innere Medizin IV, Abteilung für Gastroenterologie und Hepatologie, and Institut für Medizinische Statistik, Universtität Wien, Vienna, Austria
    Am J Gastroenterol 98:2226-31. 2003
    ..The aim of the present work was to investigate serum ASCA levels during the courses of prednisolone and mesalamine therapy in CD patients...
  52. doi request reprint Guidelines on the use of extracorporeal photopheresis
    R Knobler
    Department of Dermatology, Medical University of Vienna, Vienna, Austria
    J Eur Acad Dermatol Venereol 28:1-37. 2014
    ..Among the major studied conditions are graft versus host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection and inflammatory bowel disease...
  53. doi request reprint [Probiotics for the prevention of antibiotic-induced diarrhea]
    A Eser
    Universitätsklinik für Innere Medizin III, Medizinische Universität Wien, Osterreich
    Z Gastroenterol 50:1089-95. 2012
    ..Based on their efficacy and clinical data, different levels of evidence and recommendations are emerging on the preventive use of probiotics in antibiotic-associated diarrhoea...
  54. ncbi request reprint Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production
    Christoph Gasche
    Department of Medicine 4, Division of Gastroenterology and Hepatology, University of Vienna, Vienna, Austria
    J Immunol 170:5578-82. 2003
    ..In addition, these IL-10R1 variants had no influence on the IL-10R1 expression density. Structural analysis of the S138G variant revealed that the substitution of S138G may interfere with binding of IL-10 to IL-10R1...
  55. doi request reprint NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease
    Sieglinde Angelberger
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University Vienna, Vienna, Austria
    Am J Gastroenterol 103:1197-202. 2008
    ..The aim of the study was to explore systematically the association between NOD2/CARD15 variants and clinical response of perianal fistulas in patients using antibiotic therapy...
  56. ncbi request reprint Assessing the demand for psychological care in chronic diseases: development and validation of a questionnaire based on the example of inflammatory bowel disease
    Wolfgang Miehsler
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Austria
    Inflamm Bowel Dis 10:637-45. 2004
    ....
  57. ncbi request reprint Prospective pilot study of recombinant granulocyte-macrophage colony-stimulating factor and interferon-gamma in patients with inoperable hepatocellular carcinoma
    Walter Reinisch
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    J Immunother 25:489-99. 2002
    ..Immunotherapeutic approaches hold promise to prolong survival in selected patients with advanced HCC who respond by enhanced tumor immunogenicity...
  58. ncbi request reprint Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma
    Margareta Holub
    Department of Gastroenterology and Hepatology, University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Eur J Gastroenterol Hepatol 15:119-26. 2003
    ..Conflicting results have been reported recently on the expression and function of CD40 in carcinomas. The aim of the present study was to investigate the role of CD40 in human hepatoma...
  59. doi request reprint Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnostics
    Wolfgang Tillinger
    1st Medical Department, Hietzing Hospital, Wolkersbergenstrasse 1, Vienna, Austria
    Am J Gastroenterol 104:102-9. 2009
    ....
  60. ncbi request reprint 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension
    Arnulf Ferlitsch
    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Am J Gastroenterol 102:2495-503. 2007
    ..An influence of 6-TG on portal pressure remains to be determined. The aim of the study was to examine the functional relevance of long-term 6-TG treatment on hepatic hemodynamics in IBD patients and its association with NRH...
  61. ncbi request reprint Impact of interobserver disagreement on phenotype-genotype associations in Crohn's disease
    Anna Oefferlbauer-Ernst
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria
    Inflamm Bowel Dis 13:156-63. 2007
    ..We determined interobserver agreement on applications of definitions of the Vienna Classification variables and computed the potential influence of misclassification on genotype/phenotype associations...
  62. ncbi request reprint Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up
    Heimo H Wenzl
    Department of Internal Medicine, Karl Franzens University Graz, Austria
    Eur J Gastroenterol Hepatol 16:767-73. 2004
    ..To determine the nationwide experience with infliximab for the treatment of Crohn's disease in Austria...
  63. ncbi request reprint Infliximab for induction and maintenance therapy for ulcerative colitis
    Paul Rutgeerts
    University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 353:2462-76. 2005
    ..Infliximab, a chimeric monoclonal antibody directed against tumor necrosis factor alpha, is an established treatment for Crohn's disease but not ulcerative colitis...
  64. ncbi request reprint The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients
    Brian G Feagan
    Robarts Research Institute, University of Western Ontario, London, Canada
    Am J Gastroenterol 102:794-802. 2007
    ..The impact of infliximab induction and maintenance therapy on health-related quality of life (HRQL) was evaluated in patients with ulcerative colitis (UC)...
  65. ncbi request reprint Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease?
    Marieluise Harrer
    Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, University Clinic of Vienna, Austria
    Eur J Gastroenterol Hepatol 15:1281-5. 2003
    ....
  66. ncbi request reprint Complications in Crohn's disease: right-sided ureteric stenosis and hydronephrosis
    Sieglinde Angelberger
    Inflamm Bowel Dis 13:1056-7. 2007
  67. ncbi request reprint Steroid dependency in Crohn's disease
    Walter Reinisch
    Gastroenterology 123:393-5; author reply 395. 2002
  68. pmc A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon
    Klaus Fellermann
    Department of Internal Medicine I, Robert Bosch Hospital, 70376 Stuttgart, Germany
    Am J Hum Genet 79:439-48. 2006
    ..033). In conclusion, a lower HBD-2 gene copy number in the beta-defensin locus predisposes to colonic CD, most likely through diminished beta-defensin expression...
  69. ncbi request reprint Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations
    Peter Laszlo Lakatos
    1st Department of Medicine, Semmelweis University, Koranyi str 2 A, H 1083, Hungary
    World J Gastroenterol 11:1489-95. 2005
    ..To determine common NOD2/CARD15 mutations and TLR4 D299G polymorphism in Hungarian patients with CD...
  70. ncbi request reprint The value of serologic markers in indeterminate colitis: a prospective follow-up study
    Sofie Joossens
    Gastroenterology Unit, Department of Pathology, U Z Gasthuisberg, Leuven, Belgium
    Gastroenterology 122:1242-7. 2002
    ..We evaluated the value of anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) to increase diagnostic accuracy in categorizing IC...
  71. ncbi request reprint [NOD2/CARD15 mutations and genotype-phenotype correlations in patients with Crohn's disease. Hungarian multicenter study]
    Laszlo Lakatos
    Csolnoky Ferenc Kórház, I Sz Belgyógyászati Osztály, Veszprem
    Orv Hetil 145:1403-11. 2004
    ..It has also been suggested that the presence of mutation may influence the phenotype of the disease. The aim of this study was to determine the frequency of common NOD2/CARD15 mutations in Hungarian Crohn's patients...